Targovax announces that TG02 has passed the initial safety review in the first-in-man clinical trial in colorectal cancer
Oslo, Norway, 18 December 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces that TG02 has passed the initial planned safety review in the phase Ib clinical …